Carta científica
Uso de adalimumab en una paciente con enfermedad de Crohn y psoriasis cutánea generalizada extensa que alcanza la remisión completa de las 2 enfermedades
Use of adalimumab in a patient with Crohn's disease and extensive generalised psoriasis who achieved complete remission of both conditions
Leído
16128
Vecesse ha leído el artículo
1115
Total PDF
15013
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 28 | 8 | 36 |
| 2025 11 | 152 | 26 | 178 |
| 2025 10 | 154 | 14 | 168 |
| 2025 9 | 143 | 21 | 164 |
| 2025 8 | 126 | 14 | 140 |
| 2025 7 | 141 | 9 | 150 |
| 2025 6 | 157 | 8 | 165 |
| 2025 5 | 156 | 3 | 159 |
| 2025 4 | 216 | 6 | 222 |
| 2025 3 | 226 | 8 | 234 |
| 2025 2 | 185 | 7 | 192 |
| 2025 1 | 186 | 4 | 190 |
| 2024 12 | 249 | 6 | 255 |
| 2024 11 | 225 | 8 | 233 |
| 2024 10 | 256 | 9 | 265 |
| 2024 9 | 219 | 6 | 225 |
| 2024 8 | 221 | 4 | 225 |
| 2024 7 | 231 | 6 | 237 |
| 2024 6 | 226 | 7 | 233 |
| 2024 5 | 248 | 8 | 256 |
| 2024 4 | 188 | 2 | 190 |
| 2024 3 | 187 | 8 | 195 |
| 2024 2 | 231 | 13 | 244 |
| 2024 1 | 203 | 4 | 207 |
| 2023 12 | 192 | 8 | 200 |
| 2023 11 | 225 | 15 | 240 |
| 2023 10 | 230 | 4 | 234 |
| 2023 9 | 169 | 2 | 171 |
| 2023 8 | 227 | 2 | 229 |
| 2023 7 | 191 | 10 | 201 |
| 2023 6 | 177 | 3 | 180 |
| 2023 5 | 208 | 9 | 217 |
| 2023 4 | 135 | 3 | 138 |
| 2023 3 | 152 | 5 | 157 |
| 2023 2 | 114 | 8 | 122 |
| 2022 1 | 121 | 9 | 130 |
| 2022 12 | 97 | 9 | 106 |
| 2022 11 | 304 | 10 | 314 |
| 2022 10 | 140 | 10 | 150 |
| 2022 9 | 159 | 30 | 189 |
| 2022 8 | 154 | 17 | 171 |
| 2022 7 | 99 | 13 | 112 |
| 2022 6 | 96 | 13 | 109 |
| 2022 5 | 88 | 6 | 94 |
| 2022 4 | 83 | 11 | 94 |
| 2022 3 | 88 | 12 | 100 |
| 2022 2 | 95 | 9 | 104 |
| 2021 1 | 156 | 13 | 169 |
| 2021 12 | 94 | 15 | 109 |
| 2021 11 | 120 | 15 | 135 |
| 2021 10 | 121 | 16 | 137 |
| 2021 9 | 106 | 12 | 118 |
| 2021 8 | 101 | 12 | 113 |
| 2021 7 | 124 | 3 | 127 |
| 2021 6 | 98 | 16 | 114 |
| 2021 5 | 93 | 9 | 102 |
| 2021 4 | 214 | 20 | 234 |
| 2021 3 | 118 | 11 | 129 |
| 2021 2 | 121 | 11 | 132 |
| 2020 1 | 104 | 11 | 115 |
| 2020 12 | 127 | 7 | 134 |
| 2020 11 | 84 | 6 | 90 |
| 2020 10 | 68 | 8 | 76 |
| 2020 9 | 50 | 13 | 63 |
| 2020 8 | 78 | 16 | 94 |
| 2020 7 | 91 | 21 | 112 |
| 2020 6 | 59 | 7 | 66 |
| 2020 5 | 64 | 5 | 69 |
| 2020 4 | 53 | 4 | 57 |
| 2020 3 | 133 | 3 | 136 |
| 2020 2 | 111 | 10 | 121 |
| 2020 1 | 121 | 6 | 127 |
| 2019 12 | 80 | 9 | 89 |
| 2019 11 | 63 | 10 | 73 |
| 2019 10 | 112 | 11 | 123 |
| 2019 9 | 121 | 24 | 145 |
| 2019 8 | 79 | 2 | 81 |
| 2019 7 | 100 | 5 | 105 |
| 2019 6 | 144 | 17 | 161 |
| 2019 5 | 102 | 44 | 146 |
| 2019 4 | 168 | 11 | 179 |
| 2019 3 | 84 | 8 | 92 |
| 2019 2 | 97 | 7 | 104 |
| 2019 1 | 70 | 6 | 76 |
| 2018 12 | 51 | 5 | 56 |
| 2018 11 | 76 | 6 | 82 |
| 2018 10 | 125 | 4 | 129 |
| 2018 9 | 169 | 5 | 174 |
| 2018 8 | 46 | 1 | 47 |
| 2018 7 | 75 | 1 | 76 |
| 2018 6 | 79 | 1 | 80 |
| 2018 5 | 72 | 6 | 78 |
| 2018 4 | 107 | 1 | 108 |
| 2018 3 | 93 | 2 | 95 |
| 2018 2 | 73 | 4 | 77 |
| 2018 1 | 83 | 4 | 87 |
| 2017 12 | 71 | 2 | 73 |
| 2017 11 | 88 | 9 | 97 |
| 2017 10 | 73 | 3 | 76 |
| 2017 9 | 73 | 10 | 83 |
| 2017 8 | 98 | 1 | 99 |
| 2017 7 | 100 | 1 | 101 |
| 2017 6 | 123 | 14 | 137 |
| 2017 5 | 103 | 11 | 114 |
| 2017 4 | 89 | 2 | 91 |
| 2017 3 | 105 | 45 | 150 |
| 2017 2 | 90 | 3 | 93 |
| 2016 1 | 70 | 2 | 72 |
| 2016 12 | 48 | 5 | 53 |
| 2016 11 | 113 | 6 | 119 |
| 2016 10 | 68 | 7 | 75 |
| 2016 9 | 58 | 9 | 67 |
| 2016 8 | 54 | 4 | 58 |
| 2016 7 | 51 | 3 | 54 |
| 2016 6 | 33 | 6 | 39 |
| 2016 5 | 36 | 11 | 47 |
| 2016 4 | 21 | 8 | 29 |
| 2016 3 | 37 | 6 | 43 |
| 2016 2 | 19 | 6 | 25 |
| 2015 1 | 30 | 5 | 35 |
| 2015 12 | 39 | 7 | 46 |
| 2015 11 | 29 | 8 | 37 |
| 2015 10 | 39 | 8 | 47 |
| 2015 9 | 42 | 2 | 44 |
| 2015 8 | 19 | 5 | 24 |
| 2015 7 | 18 | 6 | 24 |
| 2015 6 | 16 | 2 | 18 |
| 2015 2 | 1 | 0 | 1 |
| 2014 11 | 0 | 1 | 1 |
| 2014 8 | 1 | 0 | 1 |
| 2013 12 | 1 | 0 | 1 |
| 2013 11 | 0 | 1 | 1 |
| 2013 10 | 2 | 0 | 2 |
| 2013 9 | 1 | 1 | 2 |
| 2013 8 | 4 | 1 | 5 |
| 2013 7 | 2 | 3 | 5 |
| 2013 5 | 172 | 0 | 172 |
Mostrar todo
